Literature DB >> 29864543

Ubiquitination: Friend and foe in cancer.

Mohammed A Mansour1.   

Abstract

Dynamic modulation and posttranslational modification of proteins are tightly controlled biological processes that occur in response to physiological cues. One such dynamic modulation is ubiquitination, which marks proteins for degradation via the proteasome, altering their localization, affecting their activity, and promoting or interfering with protein interactions. Hence, ubiquitination is crucial for a plethora of physiological processes, including cell survival, differentiation and innate and adaptive immunity. Similar to kinases, components of the ubiquitination system are often deregulated, leading to a variety of diseases, such as cancer and neurodegenerative disorders. In a context-dependent manner, ubiquitination can regulate both tumor-suppressing and tumor-promoting pathways in cancer. This review outlines how components of the ubiquitination systems (e.g. E3 ligases and deubiquitinases) act as oncogenes or tumor suppressors according to the nature of their substrates. Furthermore, I interrogate how the current knowledge of the differential roles of ubiquitination in cancer lead to technical advances to inhibit or reactivate the components of the ubiquitination system accordingly.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Deubiquitinating enzyme; E3 ligases; Hydrophobic tag; MDM2; P53; PROTAC; SCF complex; ubiquitin–proteasome system

Mesh:

Substances:

Year:  2018        PMID: 29864543     DOI: 10.1016/j.biocel.2018.06.001

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  64 in total

Review 1.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 2.  Cyclin D degradation by E3 ligases in cancer progression and treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  Semin Cancer Biol       Date:  2020-01-30       Impact factor: 15.707

Review 3.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

Review 4.  Proteolysis-targeting chimeras in drug development: A safety perspective.

Authors:  Kevin Moreau; Muireann Coen; Andrew X Zhang; Fiona Pachl; M Paola Castaldi; Goran Dahl; Helen Boyd; Clay Scott; Pete Newham
Journal:  Br J Pharmacol       Date:  2020-02-25       Impact factor: 8.739

5.  LncRNA AIRN influences the proliferation and apoptosis of hepatocellular carcinoma cells by regulating STAT1 ubiquitination.

Authors:  Huajie Cai; Yihu Zheng; Zhengde Wen; Yingnan Yang; Shouzhang Yang; Qiyu Zhang
Journal:  Arch Pharm Res       Date:  2021-03-24       Impact factor: 4.946

6.  TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation.

Authors:  Mi Chen; Shreyas Lingadahalli; Nitin Narwade; Kate Man Kei Lei; Shanshan Liu; Zuxianglan Zhao; Yimin Zheng; Qian Lu; Alexander Hin Ning Tang; Terence Chuen Wai Poon; Edwin Cheung
Journal:  EMBO Rep       Date:  2022-07-04       Impact factor: 9.071

7.  VEZF1, destabilized by STUB1, affects cellular growth and metastasis of hepatocellular carcinoma by transcriptionally regulating PAQR4.

Authors:  Xiaobao Shi; Pengfei Zhao; Gang Zhao
Journal:  Cancer Gene Ther       Date:  2022-10-14       Impact factor: 5.854

8.  NEDD4L represses prostate cancer cell proliferation via modulating PHF8 through the ubiquitin-proteasome pathway.

Authors:  Rui Feng; Zhongxing Li; Guangcheng Ge; Chenghao Wang; Yuejun Jia; Jun Ouyang
Journal:  Clin Transl Oncol       Date:  2022-09-22       Impact factor: 3.340

Review 9.  The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme.

Authors:  Semer Maksoud
Journal:  Mol Neurobiol       Date:  2021-03-04       Impact factor: 5.682

Review 10.  Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?

Authors:  Laetitia Lesire; Florence Leroux; Rebecca Deprez-Poulain; Benoit Deprez
Journal:  Cells       Date:  2022-04-05       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.